Our consultant directory offers information on who our consultants are, their specialities and where they are based.
If you have an enquiry relating to your appointment or your treatment, you should contact the relevant department instead of your individual consultant to ensure that our clinical support team can provide you with the right support to your enquiry in a timely manner.
Our consultant directory offers information on who our consultants are, their specialities and where they are based.
If you have an enquiry relating to your appointment or your treatment, you should contact the relevant department instead of your individual consultant to ensure that our clinical support team can provide you with the right support to your enquiry in a timely manner.
Dr Auer is a Consultant Haematologist at St Bartholomew’s Hospital and an Honorary Clinical Senior Lecturer at Barts Cancer Institute. She specialises in the treatment of malignant lymphoma and the use of high dose chemotherapy and stem cell transplantation for lymphoma.
She qualified from the University of Birmingham in 1993. She completed her haematology training at St Bartholomew’s Hospital with the award of her CCT in Haematology in 2007. As a Leukaemia Research Fund Clinical Research Fellow, she undertook a PhD in the molecular genetics of chronic lymphocytic leukaemia. In 2002 she was awarded the prestigious Leukaemia Research Fund / Academy of Medical Sciences Clinician Scientist award and, in 2007, a HEFCE Clinical Senior Lectureship Award which she undertook at Barts Cancer Institute.
She has a particular interest in clinical trial research for lymphoma and has extensive experience as Chief Investigator including the national front-line studies in waldenstrom macroglobulinemia, currently RAINBOW and prior to this R2W. She is part of the national group developing treatment guidelines for WM.
Dr Auer has published over 30 research papers. She is a member of the UK National Cancer Research Institute (NCRI) Low-grade lymphoma study group. She has previously been a member of the NCRI Lymphoma Research Group and an Associate Editor for the British Journal of Haematology.
• Treatment of lymphoma
• Stem cell transplantation
• Clinical trials
• Chief Investigator for RAINBOW trial
• PI on numerous trials
• Author on BCSH guidelines for management of Waldenstrom macroglobulinaemia (2022)
Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, Hernández-Rivas J-A, Qi K, Deshpande S, Parisi L, and Wang M. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow-up from a pooled analysis. (2019) Haematologica; 104(5):e211-e214.
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera J, Williams M, Barrientos J, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon S, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel L, Blum KA. Targeting Bruton’s Tyrosine Kinase with Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma. NEJM 2013 369(6):507-16.
Auer RL et al: T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies. Br J Haematol. 2012 157:580-5.
• NCRI Lymphoma Group member 2013- 2019
• Member of Pathway Board for Haematological Malignancies for the ICS London Cancer
• Associate Editor British Journal of Haematology 2004-2019
• Scientific Secretary British Society of Haematology 2011-2015
We know some websites can be confusing and hard to navigate.
Please complete this short survey about your experience today